Author:
Duggan Sean,Keam Susan J.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99.
2. Mohamed MF, Beck D, Camp HS, et al. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol. 2020;60(2):188–97.
3. European Medicines Agency. Rinvoq (upadacitinib) 15 mg prolonged-release tablets: EU summary of product characteristics. 2019. https://www.ema.europa.eu/. Accessed 14 Jul 2020.
4. AbbVie. RINVOQ™ (upadacitinib) extended-release tablets, for oral use: US prescribing information. 2019. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 14 Jul 2020.
5. Biggioggero M, Becciolini A, Crotti C, et al. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019;8:212595.